SCHEMBL29629507

SCHEMBL29629507

CC1CCN(C(=O)OC(C)(C)C)/C(=C\N(C)C)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.36
▸ DDB1 Q16531 2/20 0.34
▸ CRBN Q96SW2 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ GPR119 Q8TDV5 2/20 0.32
▸ ELANE P08246 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.32
▸ PTPN2 P17706 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ PTPN6 P29350 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608351 1.00 KDM1A (0.36) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL23608553 0.84 KDM1A (0.34) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL23580150 0.84 KDM1A (0.34) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL23580457 0.80 — —
SCHEMBL4253428 0.77 BRD4 (0.34) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL28850072 0.75 DDB1 (0.33) KDM1ADDB1CRBNELANE
SCHEMBL23608642 0.75 DDB1 (0.33) KDM1ADDB1CRBNELANE
SCHEMBL625914 0.75 PDE4A (0.44) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL14927315 0.75 PDE4A (0.44) KDM1ADDB1CRBNKDM4EMAPT
SCHEMBL8276850 0.75 PDE4A (0.44) KDM1ADDB1CRBNKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169645-A1 COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF Eternity Bioscience Inc. 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169645-A1 COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF BTK, LYN, LCK KDM1A 1691/4885DDB1 1013/4885CRBN 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback